Navigation Links
SphygmoCor Px Central Blood Pressure Assessment and Management System

ProductsSphygmoCor Px Central Blood Pressure Assessment and Management System
Company AtCor Medical Pty Ltd.
Item SphygmoCor Px Central Blood Pressure Assessment and Management System
Features The SphygmoCor Px Central Blood Pressure Assessment and Management System has transformed cardiovascular evaluation, enhancing patient assessment and management by providing the following information:
  • Evaluation of systemic arterial stiffness (Aortic Augmentation Index) and its clinical impact on the heart in increasing patient risk of heart failure, stroke and myocardial ischaemia.
  • Augmentation pressure, which drives left ventricular load (afterload) - a key parameter affecting risk of LV hypertrophy.
  • Central Pulse pressure in the ascending aorta (driving cerebral blood flow) giving the true pressure, and hence the risk of stroke.
  • Central systolic pressure, often markedly different from the cuff value.
  • Ejection duration a parameter for distinguishing primarily systolic from primarily diastolic dysfunction, and for managing the efficacy of heart failure therapy.
  • Diastolic pressure-time index (DPTI), a key determinant of coronary blood supply.
  • Systolic pressure-time index (SPTI), a measure of myocardial oxygen demand.
  • Subendocardial Viability Ratio the relationship of DPTI and SPTI, providing a powerful index for risk stratification for myocardial ischaemia.
Description The SphygmoCor Px Central Blood Pressure Assessment and Management System provides a quick and non-invasive method of obtaining central blood pressure and other key cardiovascular data, and is intended to enhance the treatment and management of patients.

Using a validated generalized transfer function, the system derives the ascending aortic blood pressure waveform from the radial arterial pressure waveform. SphygmoCor then analyzes the central aortic waveform to central pressures and other provide key indices of arterial stiffness and cardiovascular risk. These indices include aortic augmentation pressure, aortic augmentation index, ejection duration, and Buckberg Index (subendocardial viability ratio). Data are reported against age- and gender-specific reference normals.

Info AtCor Medical Pty Ltd.
Customer Service: (630) 799-8217
Web site: http://www.atcormedical.com/

Related medicine products :

1. SphygmoCor Vx Central Blood Pressure/Pulse Wave Velocity System
2. SphygmoCor Mx Central Blood Pressure Monitoring System
3. SphygmoCor Px Pulse Wave Analysis System test
4. Innotrac Aio! Central
5. Endoalpha Centralized O.R. Control System
6. Centralized Holter Analysis
7. S/5 iCentral
8. Acuity LT Central Station
9. Mobile Acuity LT™ Central Station
10. Acuity® Central Station
11. Oxinet III Central Station Network
Other Medicine News:Health News:Baicalin might be a promising therapeutic tool for severe acute pancreatitis 2Health News:Ocular Pharma Company Charlesson Announces $2.35MM in New Funding 2Health News:Ocular Pharma Company Charlesson Announces $2.35MM in New Funding 3Health News:Ocular Pharma Company Charlesson Announces $2.35MM in New Funding 4Health News:Ocular Pharma Company Charlesson Announces $2.35MM in New Funding 5Health News:BIDMC Dyslexia Research Lab celebrates 25th anniversary 2Health News:Release 1.3 of SLIM Search Now Available 2Health News:New Cleveland Clinic Press Healthy Cookbook Helps Diabetic Kids 2Health News:ImClone and Bristol-Myers Squibb Announce Joint Agreement With Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan 2Health News:ImClone and Bristol-Myers Squibb Announce Joint Agreement With Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan 3Health News:ImClone and Bristol-Myers Squibb Announce Joint Agreement With Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan 4Health News:ImClone and Bristol-Myers Squibb Announce Joint Agreement With Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan 5Health News:ImClone and Bristol-Myers Squibb Announce Joint Agreement With Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan 6Health News:ImClone and Bristol-Myers Squibb Announce Joint Agreement With Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan 7
Breaking Medicine Technology:Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies 2Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies 3Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies 4Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies 5Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies 6Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies 7GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 2GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 3GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 4GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 5GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 6Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 2Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 3Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 4IMAGINE Software Unveils Advanced IMAGINEradiology 28TM 29 Features 47841 1IMAGINE Software Unveils Advanced IMAGINEradiology 28TM 29 Features 47841 2Americas Future Now Straw Poll 3A Progressives See Health Care Reform With Public Option As Top Priority 47838 1Americas Future Now Straw Poll 3A Progressives See Health Care Reform With Public Option As Top Priority 47838 2Medical Insurance Automotive and Safety Groups Call on Congress to Make This the 22Last Deadly Summer for Teens 22 by Swiftly Passing Federal Teen 47835 1Medical Insurance Automotive and Safety Groups Call on Congress to Make This the 22Last Deadly Summer for Teens 22 by Swiftly Passing Federal Teen 47835 2Medical Insurance Automotive and Safety Groups Call on Congress to Make This the 22Last Deadly Summer for Teens 22 by Swiftly Passing Federal Teen 47835 3